Abstract
As the COVID-19 pandemic continues to affect communities across the globe, the need to contain the spread of the outbreaks is of paramount importance. Wastewater monitoring of the SARS-CoV-2 virus, the causative agent responsible for COVID-19, has emerged as a promising tool for health officials to anticipate outbreaks. As interest in wastewater monitoring continues to grow and municipalities begin to implement this approach, there is a need to further identify and evaluate methods used to concentrate SARS-CoV-2 virus RNA from wastewater samples. Here we evaluate the recovery, cost, and throughput of five different concentration methods for quantifying SARS-CoV-2 virus RNA in wastewater samples. We tested the five methods on six different wastewater samples. We also evaluated the use of a bovine coronavirus vaccine as a process control and pepper mild mottle virus as a normalization factor. Of the five methods we tested head-to-head, we found that HA filtration with bead beating performed the best in terms of sensitivity and cost. This evaluation can serve as a guide for laboratories establishing a protocol to perform wastewater monitoring of SARS-CoV-2.
Highlights
Five methods for concentrating SARS-CoV-2 RNA from wastewater evaluated
Method performance characterized via recovery, cost, throughput, and variability
HA filtration with bead beating had highest recovery for comparatively low cost
Bovine coronavirus, pepper mild mottle virus assessed as possible recovery controls
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Houston Health Department, grants from the National Science Foundation (CBET 2029025), and Rice University. P.K. was funded by a Johnson & Johnson WiSTEM2D award. Z.W.L. was funded by an Environmental Research & Education Foundation scholarship and Rice University. P.A. was funded by a National Science Foundation award (CBET 1932000). T.C. was funded by the National Academies of Science, Engineering, and Medicine Gulf Research Early Career Research Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data can be found in the body of the manuscript itself or in the supplementary information.
